Αποτελέσματα Αναζήτησης
26 Απρ 2016 · Less cardiotoxicity is seen with TCH (docetaxel, carboplatin, and trastuzumab) than with AC→TH (doxorubicin and cyclophosphamide→docetaxel and trastuzumab), and TCH is recommended for patients at higher risk for cardiotoxicity.*
AC (Adriamycin® + Cyclophosphamide) followed by THP (Taxol® + Herceptin® + Pertuzumab) is a Chemotherapy Regimen for Breast Cancer - early stage. How does AC-THP work? Doxorubicin, cyclophosphamide, and paclitaxel are chemotherapy drugs designed to kill or slow the growth of cancer cells.
8 Οκτ 2014 · Based on these data, TC is considered a standard regimen for adjuvant therapy for node-negative or low-risk node-positive breast cancer. 25 For high-risk breast cancer, good evidence suggests that four cycles of TC is inferior to sequential AC-T (even when concurrent anthracycline is added to TC). 26, 27 Although AC-T has superior breast cancer ...
6 Οκτ 2011 · The risk–benefit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity and leukemia.
13 Σεπ 2019 · The NSABP B-31 compared AC-T regimen, i.e., four cycles of doxorubicin plus cyclophosphamide (AC) followed by four sequential cycles of paclitaxel every 3 weeks with AC-TH regimen, i.e ...
7 Δεκ 2022 · INTRODUCTION. The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.
Results: In this study (N = 121), pCR was numerically higher with pertuzumab based regimens, including ddAC-THP (60%), TCHP (63%), THP (55%), as compared with ddAC-TH (46%). THP resulted in significantly less cycle delays due to toxicity compared to the other regimens (p=0.02).
